✦ LIBER ✦

RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH THE INTERLEUKIN-6 RECEPTOR INHIBITOR TOCILIZUMAB

✍ Scribed by Rao, Vijay Udyavar; Pavlov, Andrey; Klearman, Micki; Musselman, David; Giles, Jon; Bathon, Joan M.; Sattar, Naveed; Lee, Janet S.

Book ID: 122789483
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 89 KB
Volume: 59
Category: Article
ISSN: 1558-3597
DOI: 10.1016/S0735-1097(12)61649-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Baseline levels of soluble interleukin-6

Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy

✍ Nishina, N.; Kikuchi, J.; Hashizume, M.; Yoshimoto, K.; Kameda, H.; Takeuchi, T. 📂 Article 📅 2013 🏛 BMJ Publishing Group 🌐 English ⚖ 705 KB

Incidence and Risk Factors for Serious I

Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety

✍ KOMANO, Y.; TANAKA, M.; NANKI, T.; KOIKE, R.; SAKAI, R.; KAMEDA, H.; NAKAJIMA, A 📂 Article 📅 2011 🏛 Journal of Rheumatology Publishing Company 🌐 English ⚖ 337 KB

The risk of serious infection in patient

The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database

✍ Sakai, Ryoko; Cho, Soo-Kyung; Nanki, Toshihiro; Koike, Ryuji; Watanabe, Kaori; Y 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 250 KB

Humanized anti-interleukin-6-receptor an

Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study

✍ Jun Hashimoto; Patrick Garnero; Désirée van der Heijde; Nobuyuki Miyasaka; Kazuh 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 191 KB

Re-evaluation of the risk for major adve

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials

✍ T. Tzellos; A. Kyrgidis; C. C. Zouboulis 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 254 KB

Rapid and sustained improvement in bone

Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone

✍ Patrick Garnero; Elizabeth Thompson; Thasia Woodworth; Josef S. Smolen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 276 KB 👁 3 views

## Abstract ## Objective To investigate the effects of tocilizumab (TCZ) added to a stable dosage of methotrexate (MTX) on biochemical markers of bone and cartilage metabolism in patients in the multicenter double‐blind, placebo‐controlled OPTION (Tocilizumab Pivotal Trial in Methotrexate Inadequa